| Citation: |
XING Xiaoke, WANG Shuxian, LI Juanjuan, SONG Qibin, ZHANG Pingfeng. Progress of Research on ABC Transporters in Tumor Multidrug Resistance[J]. Cancer Research on Prevention and Treatment, 2024, 51(7): 594-599. DOI: 10.3971/j.issn.1000-8578.2024.24.0082
|
The ATP-binding cassette (ABC) transporter superfamily comprises membrane proteins that efflux various substrates across extra- and intracellular membranes. Among them, ABCB1, ABCG2, and ABCC1 are directly linked to tumor multidrug resistance (MDR). This review provides an overview of the current understanding on the novel mechanisms and functions of ABCB1, ABCG2, and ABCC1 transporters in tumor MDR, discusses the latest strategies to target these transporters, and explores further opportunities to overcome MDR.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Baril SA, Gose T, Schuetz JD. How Cryo-EM has expanded our understanding of membrane transporters[J]. Drug Metab Dispos, 2023, 51(8): 904-922. doi: 10.1124/dmd.122.001004
|
| [2] |
Fan J, To KKW, Chen ZS, et al. ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance[J]. Drug Resistance Updates, 2023, 66: 100905. doi: 10.1016/j.drup.2022.100905
|
| [3] |
Bloch M, Raj I, Pape T, et al. Structural and mechanistic basis of substrate transport by the multidrug transporter mrp4[J]. Structure, 2023, 31(11): 1407-1418. e6.
|
| [4] |
Duvivier L, Gerard L, Diaz A, et al. Linking ABC transporters to the hallmarks of cancer[J]. Trends Cancer, 2024, 10(2): 124-134. doi: 10.1016/j.trecan.2023.09.013
|
| [5] |
Villa M, Wu J, Hansen S, et al. Emerging role of ABC transporters in glia cells in health and diseases of the central nervous system[J]. Cells, 2024, 13(9): 740. doi: 10.3390/cells13090740
|
| [6] |
Bodó A, Bakos E, Szeri F, et al. The role of multidrug transporters in drug availability, metabolism and toxicity[J]. Toxicol Lett, 2003, 140-141: 133-143. doi: 10.1016/S0378-4274(02)00497-6
|
| [7] |
Pote MS, Gacche RN. ATP-binding cassette efflux transporters and MDR in cancer[J]. Drug Discov Today, 2023, 28(5): 103537. doi: 10.1016/j.drudis.2023.103537
|
| [8] |
Mohammad IS, He W, Yin L. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR[J]. Biomed Pharmacother, 2018, 100: 335-348. doi: 10.1016/j.biopha.2018.02.038
|
| [9] |
Locher KP. Mechanistic diversity in ATP-binding cassette (ABC) transporters[J]. Nat Struct Mol Biol, 2016, 23(6): 487-493. doi: 10.1038/nsmb.3216
|
| [10] |
Gewering T, Waghray D, Parey K, et al. Tracing the substrate translocation mechanism in P-glycoprotein[J]. ELife, 2024, 12: RP90174. doi: 10.7554/eLife.90174.3
|
| [11] |
Kowal J, Ni D, Jackson SM, et al. Structural basis of drug recognition by the multidrug transporter ABCG2[J]. J Mol Biol, 2021, 433(13): 166980. doi: 10.1016/j.jmb.2021.166980
|
| [12] |
Wang L, Johnson ZL, Wasserman MR, et al. Characterization of the kinetic cycle of an ABC transporter by single-molecule and cryo-EM analyses[J]. ELife, 2020, 9: e56451. doi: 10.7554/eLife.56451
|
| [13] |
Johnson ZL, Chen J. Structural basis of substrate recognition by the multidrug resistance protein MRP1[J]. Cell, 2017, 168(6): 1075-1085. e9.
|
| [14] |
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer[J]. Cancer Drug Resist, 2019, 2(2): 141-160.
|
| [15] |
Haider T, Pandey V, Banjare N, et al. Drug resistance in cancer: Mechanisms and tackling strategies[J]. Pharmacol Rep, 2020, 72(5): 1125-1151. doi: 10.1007/s43440-020-00138-7
|
| [16] |
Zhang M, Huang MN, Dong XD, et al. Overexpression of ABCB1 confers resistance to FLT3 inhibitor FN-1501 in cancer cells: In vitro and in vivo characterization[J]. Am J Cancer Res, 2023, 13(12): 6026-6037.
|
| [17] |
Souza PS, Madigan JP, Gillet JP, et al. Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL[J]. Exp Cell Res, 2015, 336(2): 318-328. doi: 10.1016/j.yexcr.2015.06.005
|
| [18] |
Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells[J]. Proc Natl Acad Sci U S A, 1998, 95(26): 15665-15670. doi: 10.1073/pnas.95.26.15665
|
| [19] |
Ross DD, Nakanishi T. Impact of breast cancer resistance protein on cancer treatment outcomes[J]. Methods Mol Biol, 2010, 596: 251-290.
|
| [20] |
Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)[J]. Oncogene, 2003, 22(47): 7340-7358. doi: 10.1038/sj.onc.1206938
|
| [21] |
Zhang L, Zhao J, Liang C, et al. A novel biosensor based on intestinal 3D organoids for detecting the function of BCRP[J]. Drug Deliv, 2017, 24(1): 1453-1459. doi: 10.1080/10717544.2017.1381199
|
| [22] |
Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line[J]. Science, 1992, 258(5088): 1650-1654. doi: 10.1126/science.1360704
|
| [23] |
Hanssen KM, Haber M, Fletcher JI. Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition[J]. Drug Resist Updat, 2021, 59: 100795. doi: 10.1016/j.drup.2021.100795
|
| [24] |
Gelbmann CB, Kalejta RF. The membrane-spanning peptide and acidic cluster dileucine sorting motif of UL138 are required to downregulate MRPl drug transporter function in human cytomegalo virus-infected cells[J]. J Virol, 2019, 93(11): e00430-19.
|
| [25] |
Chaves-Filho AB, Schulze A. Cholesterol atlas of tumor microenvironment provides route to improved CAR-T therapy[J]. Cancer Cell, 2023, 41(7): 1204-1206. doi: 10.1016/j.ccell.2023.05.013
|
| [26] |
Erin N, Grahovac J, Brozovic A, et al. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance[J]. Drug Resist Updat, 2020, 53: 100715. doi: 10.1016/j.drup.2020.100715
|
| [27] |
Kyle-Cezar F, Echevarria-Lima J, Rumjanek VM. Independent regulation of ABCB1 and ABCC activities in thymocytes and bone marrow mononuclear cells during aging[J]. Scand J Immunol, 2007, 66(2-3): 238-248. doi: 10.1111/j.1365-3083.2007.01965.x
|
| [28] |
Walther W, Kobelt D, Bauer L, et al. Chemosensitization by diverging modulation by short-term and long-term TNF-α action on ABCB1 expression and NF-κb signaling in colon cancer[J]. Int J Oncol, 2015, 47(6): 2276-2285. doi: 10.3892/ijo.2015.3189
|
| [29] |
Zheng M, Zhang W, Chen X, et al. The impact of lipids on the cancer-immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy[J]. Acta Pharm Sin B, 2023, 13(4): 1488-1497. doi: 10.1016/j.apsb.2022.10.027
|
| [30] |
Duan C, Yu M, Xu J, et al. Overcoming cancer multi-drug resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges[J]. Biomed Pharmacother, 2023, 162: 114643. doi: 10.1016/j.biopha.2023.114643
|
| [31] |
Karthikeyan S, Hoti SL. Development of fourth generation ABC inhibitors from natural products: A novel approach to overcome cancer multidrug resistance[J]. Anticancer Agents Med Chem, 2015, 15(5): 605-615. doi: 10.2174/1871520615666150113103439
|
| [32] |
Li Y, Zhai Z, Li H, et al. Guajadial reverses multidrug resistance by inhibiting abc transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells[J]. Chem Biol Interact, 2019, 305: 98-104. doi: 10.1016/j.cbi.2019.03.032
|
| [33] |
Attia YM, El-Kersh DM, Ammar RA, et al. Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer[J]. Chem Biol Interact, 2020, 315: 108865. doi: 10.1016/j.cbi.2019.108865
|
| [34] |
Feng SL, Luo HB, Cai L, et al. Ginsenoside Rg5 overcomes chemotherapeutic multidrug resistance mediated by abcb1 transporter: In vitro and in vivo study[J]. J Ginseng Res, 2020, 44(2): 247-257. doi: 10.1016/j.jgr.2018.10.007
|
| [35] |
Suemura S, Kodama T, Myojin Y, et al. CRISPR loss-of-function screen identifies the hippo signaling pathway as the mediator of regorafenib efficacy in hepatocellular carcinoma[J]. Cancers(Basel), 2019, 11(9): 1362.
|
| [36] |
Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/PGP[J]. Neoplasia, 2009, 11(1): 96-101. doi: 10.1593/neo.81264
|
| [37] |
Li LB, Yang LX, Liu L, et al. Targeted inhibition of the HNF1A/SHH axis by triptolide overcomes paclitaxel resistance in non-small cell lung cancer[J]. Acta Pharmacol Sin, 2024, 45(5): 1060-1076.
|
| [38] |
Fultang N, Illendula A, Lin J, et al. ROR1 regulates chemoresistance in breast cancer via modulation of drug efflux pump ABCB1[J]. Sci Rep, 2020, 10(1): 1821. doi: 10.1038/s41598-020-58864-0
|
| [39] |
Wang Y, Huang Z, Chen CZ, et al. Therapeutic targeting of MDR1 expression by RORγ antagonists resensitizes cross-resistant crpc to taxane via coordinated induction of cell death programs[J]. Mol Cancer Ther, 2020, 19(2): 364-374. doi: 10.1158/1535-7163.MCT-19-0327
|
| [40] |
Rabindran SK, He H, Singh M, et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C[J]. Cancer Research, 1998, 58(24): 5850-5858.
|
| [41] |
Weidner LD, Zoghbi SS, Lu S, et al. The inhibitor Ko143 is not specific for ABCG2[J]. J Pharmacol Exp Ther, 2015, 354(3): 384-393. doi: 10.1124/jpet.115.225482
|
| [42] |
Zattoni IF, Delabio LC, Dutra JP, et al. Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators[J]. Eur J Med Chem, 2022, 237: 114346. doi: 10.1016/j.ejmech.2022.114346
|
| [43] |
Wong ILK, Zhu X, Chan KF, et al. Flavonoid monomers as potent, nontoxic, and selective modulators of the breast cancer resistance protein (ABCG2)[J]. J Med Chem, 2021, 64(19): 14311-14331. doi: 10.1021/acs.jmedchem.1c00779
|
| [44] |
Bergmann TK, Stage TB, Stenvang J, et al. Four phase 1 trials to evaluate the safety and pharmacokinetic profile of single and repeated dosing of SCO-101 in adult male and female volunteers[J]. Basic Clin Pharmacol Toxicol, 2020, 127(4): 329-337. doi: 10.1111/bcpt.13466
|
| [45] |
Li H, Zhang SL, Jia YH, et al. Imidazo[1, 2-a]pyridine derivatives as novel dual-target inhibitors of ABCB1 and ABCG2 for reversing multidrug resistance[J]. J Med Chem, 2023, 66(4): 2804-2831. doi: 10.1021/acs.jmedchem.2c01862
|
| [46] |
Gekeler V, Ise W, Sanders KH, et al. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance[J]. Biochem Biophys Res Commun, 1995, 208(1): 345-352. doi: 10.1006/bbrc.1995.1344
|
| [47] |
Csandl MA, Conseil G, Cole SPC. Cysteinyl leukotriene receptor 1/2 antagonists nonselectively modulate organic anion transport by multidrug resistance proteins (mrp 1-4)[J]. Drug Metab Dispos, 2016, 44(6): 857-866.
|
| [48] |
Cole SPC. Targeting multidrug resistance protein 1 (MRP1, ABCC1): Past, present, and future[J]. Annu Rev of Pharmacol Toxicol, 2014, 54: 95-117. doi: 10.1146/annurev-pharmtox-011613-135959
|
| [49] |
Bacon NA, Larre I, Lawag AA, et al. Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-β and paclitaxel in A549 cells[J]. Biomed Pharmacother, 2020, 129: 110434. doi: 10.1016/j.biopha.2020.110434
|
| [50] |
Gao Q, Li XX, Xu YM, et al. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells[J]. Cancer Lett, 2020, 476: 67-74. doi: 10.1016/j.canlet.2020.02.007
|
| [51] |
Pietz HL, Abbas A, Johnson ZL, et al. A macrocyclic peptide inhibitor traps MRP1 in a catalytically incompetent conformation[J]. Proc Natl Acad Sci U S A, 2023, 120(11): e2220012120. doi: 10.1073/pnas.2220012120
|
| [52] |
Boehnke N, Straehla JP, Safford HC, et al. Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery[J]. Science, 2022, 377(6604): eabm5551. doi: 10.1126/science.abm5551
|
| [53] |
Kim W, Ye Z, Simonenko V, et al. Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to immune Checkpoint Inhibitors[J]. NAR Cancer, 2024, 6(1): zcad059. doi: 10.1093/narcan/zcad059
|
| [54] |
Chen J, Liu Y, Chen F, et al. Non-Faradaic optoelectrodes for safe electrical neuromodulation[J]. Nat Commun, 2024, 15(1): 405. doi: 10.1038/s41467-023-44635-8
|
| [55] |
Wang J, Li X, Wang F-F, et al. Placing steroid hormones within the human ABCC3 transporter reveals a compatible amphiphilic substrate-binding pocket[J]. EMBO J, 2023, 42(17): e113415. doi: 10.15252/embj.2022113415
|
| [1] | ZHAO Qian, LI Feng. Role and Research Progress of CD81 in Tumors[J]. Cancer Research on Prevention and Treatment, 2025, 52(3): 233-240. DOI: 10.3971/j.issn.1000-8578.2025.24.0730 |
| [2] | WANG Hao, JIN Yan, WU Nan. Advances in Research Methods of Tumor Angiogenesis[J]. Cancer Research on Prevention and Treatment, 2023, 50(7): 721-725. DOI: 10.3971/j.issn.1000-8578.2023.23.0070 |
| [3] | ZHANG Xu, XU Meng, LIU Ye, GU Xiaoxiao, QIAN Hui, XU Wenrong. Role of Nanog in Tumorigenesis and Tumor Development[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 295-299. DOI: 10.3971/j.issn.1000-8578.2016.04.012 |
| [4] | WANG Lin, HUANG Jiankun. Review on Researches of TFF3 as Tumor Biomarker[J]. Cancer Research on Prevention and Treatment, 2015, 42(11): 1156-1160. DOI: 10.3971/j.issn.1000-8578.2015.11.022 |
| [5] | LIU Chang, WANG Xie, SHEN Lijuan. Subcelluar Localization of p27kip1 and Tumour[J]. Cancer Research on Prevention and Treatment, 2015, 42(05): 522-525. DOI: 10.3971/j.issn.1000-8578.2015.05.022 |
| [6] | XIAO Bing, YE Minhua, ZHU Xingen. Advances of IKKε in Tumor[J]. Cancer Research on Prevention and Treatment, 2015, 42(01): 69-73. DOI: 10.3971/j.issn.1000-8578.2015.01.017 |
| [7] | SUN Peng, WANG Yanlin. Tumor-associated Macrophages Development and Treatment of Tumor[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 829-833. DOI: 10.3971/j.issn.1000-8578.2014.07.031 |
| [8] | HE Xusheng, WANGJian-hua, DIAO Sheng-lin. CT Study on Parotid Tumors[J]. Cancer Research on Prevention and Treatment, 2005, 32(03): 164-165. DOI: 10.3971/j.issn.1000-8578.2480 |
| [9] | JIA Shao-chang, YIN Guang-fu, XU Zheng-chang, et al, . The Frequent Somatic Mutations of Von Hippel-Lindau Tumor Suppressor Gene(VHL) and the Expression of Multiple Drug Resistence(Mdr) Gene in Human Renal Carcinomas[J]. Cancer Research on Prevention and Treatment, 2000, 27(05): 337-339. DOI: 10.3971/j.issn.1000-8578.3398 |
| [10] | Pen GuiYoug, . Study on transfer factor in killing and inhibiting tumor cells[J]. Cancer Research on Prevention and Treatment, 1994, 21(6): 360-361. |
Figures(1)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: